Johnson NP, Mueller J.
Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002; 76:105-15.
Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy. 2005; 26:4-29.
Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, deJong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005; 353:1374-85.
Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 2004; 350:1179-88.
Hsieh YC, Wu TZ, Liu DP, Shao PL, Chang LY, Lu CY, et al. Influenza pandemics: past, present and future. J Formos Med Assoc. 2006; 105:1-6.
Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol. 2001; 8:859-63.
Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005; 56:919-22.
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24:44-6.
Hellstern P, Muntean W, Schramm W, Seifried E, Solheim BG. Practical guidelines for the clinical use of plasma. Thromb Res. 2002; 107 Suppl 1:S53-7.
O'Shaughnessy DF, Atterbury C, BoltonMaggs P, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004; 126:11-28.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283:2008-12.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998; 52:377-84.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-88.
Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988; 7:889-94.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557-60.
Egger M, DaveySmith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629-34.
Stoll HF. Value of convalescent blood and serum in treatment of influenza pneumonia. JAMA. 1919; 73:478-83.
O'Malley JJ, Hartman FW. Treatment of influenzal pneumonia with plasma of convalescent patients. JAMA. 1919;72:3437.
Ross CW, Hund EJ. Transfusion on the desperate pneumonias complicating influenza—preliminary report on the successful use of total immune citrated blood. JAMA. 1918; 71:1992-3.
Ross CW, Hund EJ. Treatment of pneumonic disturbance complicating influenza. JAMA. 1919; 72:640-5.
Kahn MH. Serum treatment of postinfluenzal bronchopneumonia. JAMA. 1919;72;102-3.
Gould EW. Human serum in the treatment of influenza bronchopneumonia. New York Medical Journal. 1919; 109:666-7.
McGuire LW, Redden WR. Treatment of influenzal pneumonia by the use of convalescent human serum—preliminary report. JAMA. 1918;71:1311.
McGuire LW, Redden WR. Treatment of influenzal pneumonia by the use of convalescent human serum. JAMA. 1919; 72:709-13.
Sanborn GP. The use of the serum of convalescents in the treatment of influenza pneumonia: a summary of the results in a series of one hundred and one cases. Boston Medical and Surgical Journal. 1920; 183:171-7.
Maclachlan WW, Fetter WJ. Citrated blood in treatment of the pneumonia following influenza. JAMA. 1918; 71:2053-5.
Francis FD, Hall MW, Gaines AR. Early use of convalescent serum in influenza. Mil Surg. 1920; 47:177-9.
Redden WR. Treatment of influenza-pneumonia by use of convalescent human serum. Boston Medical and Surgical Journal. 1919; 161:688-91.
Jacobaeus. Treatment of influenza pneumonia with serum from convalescents. Svenska Lakartidnin. 1920; 18:385-99.
Lord FT. Discussion of W.R. Redden's paper. Boston Medical and Surgical Journal. 1919;161:691.
Locke EA. Discussion of W.R. Redden's paper. Boston Medical and Surgical Journal. 1919; 161:691-2.
Bass JA, Ervin CE. Use of serum in the treatment of influenza-pneumonia. Naval Medical Bulletin (Division of Sanitation). 1919; 71.
Simici D. Treatment of influenza with injections of blood from convalescents. Paris Med. 1922; 43:474-7.
Holst J. Convalescent serum in treatment of influenza. Norsk Magazine for Laegevidenskaben. 1919; 80:531-61.
Lesne E, Brodin P, Saint-Girons F. Plasma therapy in influenza. Presse Med. 1919; 27:181-2.
Ehrenberg L, Barkman A. Convalescent serum in the prevention and treatment of influenza. Hygiea. 1919; 81:113-23.
Bang O. Convalescent serum in the treatment of influenza pneumonia. Norsk Magazine for Laegevidenskaben. 1920; 81:255-261.
Bogardus FB. Influenza pneumonia treated by blood transfusions. New York Medical Journal. 1919;109:765.
Huff-Hewitt WE. Human serum in influenza. Br Med J. 1919;1:575.
Miller OO, McConnell WT. Report of influenza treated with serum from recovered cases. Ky Med J. 1919; 17:218-9.
Brown WL, Sweet BL. Treatment of influenzal pneumonia by citrated transfusions. JAMA. 1918; 71:1602-3.
Carlyle PM. Injection of whole blood in influenza. Br Med J. 1919;1:698.
Liebmann. Blatt fur Schweizer Aerzle. 12 October 1918.
Sweet C, Jakeman KJ, Smith H. Role of milk-derived IgG in passive maternal protection of neonatal ferrets against influenza. J Gen Virol. 1987;68(Pt 10):2681-6. [PMID: 3668509]
Sweet C, Bird RA, Jakeman K, Coates DM, Smith H. Production of passive immunity in neonatal ferrets following maternal vaccination with killed influenza A virus vaccines. Immunology. 1987; 60:83-9.
McClure JT, DeLuca JL, Lunn DP, Miller J. Evaluation of IgG concentration and IgG subisotypes in foals with complete or partial failure of passive transfer after administration of intravenous serum or plasma. Equine Vet J. 2001; 33:681-6.
Zhang F, Chen J, Fang F, Zhou Y, Wu J, Chang H, et al. Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice. DNA Cell Biol. 2005; 24:758-65.
Reuman PD, Ayoub EM, Small PA. Effect of passive maternal antibody on influenza illness in children: a prospective study of influenza A in mother-infant pairs. Pediatr Infect Dis J. 1987; 6:398-403.
Englund JA, Mbawuike IN, Hammill H, Holleman MC, Baxter BD, Glezen WP. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis. 1993; 168:647-56.
Virelizier JL. Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol. 1975; 115:434-139.
Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol. 1997; 71:4347-55.
Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res. 2006;7:43. [PMID: 16553963]
Takiguchi K, Sugawara K, Hongo S, Nishimura H, Kitame F, Nakamura K. Protective effect of serum antibody on respiratory infection of influenza C virus in rats. Arch Virol. 1992; 122:1-11.
Berezina AI. [Experience in treating influenza with dry anti-influenza serum of Smorodintsev; preliminary report.]. Sov Med.. 1956; 20:67-8.
Stavskaia VV, Ignateva NA. [On the treatment of influenza and influenzal pneumonia.]. Klin Med (Mosk).. 1963; 41:69-75.
Selivanov AA, Morozenko MA, Kallas EV, Nikitin MI, Nikitina LE. [Experimental for achievement of therapeutic sera against respiratory infections from immunized donors]. Vrach Delo. 1967; 1:104-6.
Zhukova EA. [Character of the therapeutic action of different schedules of administration of donor anti-influenza gamma-globulin to influenza patients]. Tr Inst Im Pastera. 1985; 63:47-51.
Firsov SL, Zhukova EA. [Experience with the clinical use of donor anti-influenza gamma-globulin]. Tr Inst Im Pastera. 1985; 63:52-5.
Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature. 2005; 437:889-93.
Siami GA, Siami FS. The current status of therapeutic apheresis devices in the United States. Int J Artif Organs. 2002; 25:499-502.
Madore F. Plasmapheresis. Technical aspects and indications. Crit Care Clin. 2002; 18:375-92.
U.S. Food and Drug Administration, Health and Human Services. Code of Federal Regulations, Title 21 640 (4-1-03 Edition); Section 640.65. Plasmapheresis:100-106. Washington, DC: U.S. Government Printing Office; 2003.
Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science. 2005; 310:77-80.